The latest data point for RXRX's Return on Sales (ROS) in Q4'25 shows a value of -3.04%, marking a notable improvement from the prior quarter's deeper loss of -31.35% in Q3'25, though the company remains in negative territory amid ongoing operational challenges. Over the period from Q2'23 to Q4'25, ROS has exhibited high volatility with an overall negative trend, starting at -6.96% and worsening to a low of -39.35% in Q4'24 before partial recoveries, including a brief uptick to -3.67% in Q3'24; significant declines in Q4'24 and Q3'25 highlight potential cost pressures or revenue shortfalls, while the area chart underscores persistent unprofitability without clear stabilization. No data is available for Q1'26, limiting forward visibility.